New hope for Ultra-Resistant schizophrenia: Anti-Inflammatory drug combo trial
NCT ID NCT05240976
First seen Mar 31, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This study is for people with schizophrenia that hasn't improved with standard treatments, including clozapine. Researchers want to see if adding an anti-inflammatory drug to an NMDA-enhancing agent can improve thinking and memory. About 80 participants will take the combination and be monitored for changes in cognitive function and symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Psychiatry, China Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.